Vaso-occlusion in children with sickle cell disease - Clinical characteristics and biologic correlates

被引:0
|
作者
Dampier, C
Setty, BNY
Eggleston, B
Brodecki, D
O'Neal, P
Stuart, M
机构
[1] St Christophers Hosp Children, Marian Anderson Comprehens Sickle Cell Ctr, Philadelphia, PA 19134 USA
[2] Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA
[3] Thomas Jefferson Univ, Sch Med, Dept Pediat, Philadelphia, PA 19107 USA
[4] Ctr Comprehens Sickle Cell, Stat & Data Management Ctr, Rho Fed Syst Div, Chapel Hill, NC USA
关键词
sickle cell disease; vaso-occlusion; pain; erythrocyte/endothelial cell adhesion;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vaso-occlusive pain is a frequent manifestation of sickle cell disease, but most clinical studies have documented only those pain episodes for which patients seek acute care or require hospitalization. Based on limited previous studies, the authors Suggest that pain episodes managed at home are more frequent then those resulting in acute care management but likely share a common pathophysiology. The authors determined the characteristics of vaso-occlusive pain managed at home in 30 subjects (ages 6-19 years) using a self-report diary daily for 6 months. A total of 175 pain episodes were reported in 4,885 days, with 51% lasting 1 day or less. Severe pain, rated as 7 to 10 on a 10-point scale, was reported on 12% of pain days, but most pain was of mild to moderate intensity. A combination of baseline hematologic parameters and biomarkers assessing erythrocyte/endothelial cell adhesion, including hematocrit, fetal hemoglobin, and adhesion ratio, were statistically significant predictors of pain frequency in statistical analyses. Given the overlap in clinical features and predictive hematologic parameters of home-managed and acute care-managed pain, both likely represent a continuum of frequency and severity rather than distinct clinical entities. The higher frequency of these home-managed episodes suggests their potential utility as additional outcome measures in Studies of vaso-occlusive pain.
引用
收藏
页码:785 / 790
页数:6
相关论文
共 50 条
  • [1] Sickle cell vaso-occlusion
    Chiang, EY
    Frenette, PS
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2005, 19 (05) : 771 - +
  • [2] The 'scintilla' starting vaso-occlusion in sickle cell disease
    Piccin, Andrea
    Magzoub, Ibrahim
    Hervig, Tor
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 379 - 380
  • [3] The Physical Foundation of Vaso-Occlusion in Sickle Cell Disease
    Aprelev, Alexey
    Stephenson, William
    Noh, Hongseok
    Meier, Maureen
    Ferrone, Frank A.
    [J]. BIOPHYSICAL JOURNAL, 2013, 104 (02) : 677A - 677A
  • [4] Newer Aspects of the Pathophysiology of Sickle Cell Disease Vaso-Occlusion
    Conran, Nicola
    Franco-Penteado, Carla F.
    Costa, Fernando F.
    [J]. HEMOGLOBIN, 2009, 33 (01) : 1 - 16
  • [5] RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease
    Burnette, Angela D.
    Nimjee, Shahid M.
    Batchvarova, Milena
    Zennadi, Rahima
    Telen, Marilyn J.
    Nishimura, Jun-ichi
    Sullenger, Bruce A.
    [J]. NUCLEIC ACID THERAPEUTICS, 2011, 21 (04) : 275 - 283
  • [6] Sickle cell vaso-occlusion: the clot thickens
    Gordeuk, Victor R.
    [J]. BLOOD, 2020, 135 (20) : 1726 - 1727
  • [7] Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
    Manwani, Deepa
    Frenette, Paul S.
    [J]. BLOOD, 2013, 122 (24) : 3892 - 3898
  • [8] Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
    Manwani, Deepa
    Frenette, Paul S.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 362 - 369
  • [9] Molecular and cellular mechanism of systemic vaso-occlusion in Sickle Cell Disease
    Jimenez, Maritza
    Sundd, Prithu
    [J]. FASEB JOURNAL, 2014, 28 (01):
  • [10] Sickle cell vaso-occlusion: multistep and multicellular paradigm
    Frenette, PS
    [J]. CURRENT OPINION IN HEMATOLOGY, 2002, 9 (02) : 101 - 106